Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Arecor Limited is currently managing 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 5 distinct examiners, indicating a high degree of examiner variety. The portfolio is spread across 5 distinct art units, reflecting a broad technical range within the biotech sector.
D' AMBROSIO, THEA is the busiest examiner, responsible for 2 pending office actions. The ratio of 5 distinct examiners to 6 pending office actions shows that most cases are being reviewed by different individuals. D' AMBROSIO, THEA is the only examiner with more than one pending action, holding 2 of the 6 total.
This distribution requires the company to manage 5 separate examiner relationships. The 5 distinct art units further emphasize the technical breadth of the 6 pending office actions. For practitioners, the primary challenge is the fragmentation of the portfolio, as there is limited opportunity for a unified prosecution strategy across the 5 distinct art units.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| Double-patenting + other | 3 (50%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| D' AMBROSIO, THEA | 2 | 55.3% | +56.1% |
| WAX, ROBERT A | 1 | 25.0% | +3.9% |
| KIM, YUNSOO | 1 | 65.9% | +34.3% |
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
| O'BRIEN, LEA S | 1 | 51.4% | +13.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18866851 | COMPOSITIONS COMPRISING VANCOMYCIN | WAX, ROBERT A | — |
| 18243767 | STABILIZED ANTIBODY PROTEIN SOLUTIONS | KIM, YUNSOO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17428341 | STABILIZED Fc FUSION PROTEIN SOLUTIONS | O'BRIEN, LEA S | 176d overdue |
| 17416845 | NOVEL COMPOSITION | D' AMBROSIO, THEA | 98d overdue |
| 17916504 | NOVEL FORMUATIONS | RODRIGUEZ, RAYNA B | 50d overdue |
| 18243767 | STABILIZED ANTIBODY PROTEIN SOLUTIONS | KIM, YUNSOO | — |
| 17044706 | MEDICAL INFUSION PUMP SYSTEM FOR THE DELIVERY OF AN INSULIN COMPOUND | D' AMBROSIO, THEA | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| 1615 | 1 |
| 1641 | 1 |
| 1628 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18866851 | COMPOSITIONS COMPRISING VANCOMYCIN | WAX, ROBERT A | 1615 | §103§112 | Non-Final OA | — | Pending | Nov 18, 2024 |
| 18243767 | STABILIZED ANTIBODY PROTEIN SOLUTIONS | KIM, YUNSOO | 1641 | §102§103§112Other | Non-Final OA | — | Pending | Sep 08, 2023 |
| 17916504 | NOVEL FORMUATIONS | RODRIGUEZ, RAYNA B | 1628 | §102§112DP | Final Rejection | 50d overdue | Pending | Sep 30, 2022 |
| 17428341 | STABILIZED Fc FUSION PROTEIN SOLUTIONS | O'BRIEN, LEA S | 1646 | §103 | Non-Final OA | 176d overdue | Pending | Aug 04, 2021 |
| 17416845 | NOVEL COMPOSITION | D' AMBROSIO, THEA | 1654 | §103DP | Final Rejection | 98d overdue | Pending | Jun 21, 2021 |
| 17044706 | MEDICAL INFUSION PUMP SYSTEM FOR THE DELIVERY OF AN INSULIN COMPOUND | D' AMBROSIO, THEA | 1654 | §103§112DP | Non-Final OA | — | Pending | Oct 01, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial